You are here:

Scientific programme

Wednesday May 22, 2019

12:00-12:45 Registration

12:45-13:00 Welcome

  • Cai Grau, Aarhus (DK)

13:00-14:40 Session 1: Radiobiology: genomics, biomarkers, functional imaging, personalized medicine

Moderators: Heidi Lyng and Jens Overgaard

Invited speakers (20 min):

  • Rob Bristow, Manchester (UK): A deep dive into the genomics of hypoxia tumours - implications for precision cancer medicine
  • Daniel Zips, Tübingen (DE): Biologically-individualized real-time MR-guided radiotherapy: concept, prerequisites and first clinical experience
  • Eirik Malinen, Oslo (NO): Dynamic imaging and pharmacokinetic modelling - from biology to physics and back
  • Esther Troost, Dresden (DE): Functional imaging for tumor and normal tissue response prediction

Proffered papers (10 min):

  • Jacob Lilja-Fischer, Aarhus (DK): Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts
  • Christina Sæten Fjeldbo, Oslo (NO): Treatment decision support by imaging- and gene-based hypoxia classification in cervical cancer

Coffee break

15:10-16:40 Session 2: Building clinical evidence for particle therapy – the European approach

Moderators: Dirk De Ruysscher and Morten Høyer

Panelists (10 min):

  • Damien Weber, Villigen (CH)
  • Karin Haustermans, Leuven (BE)
  • Esther Troost, Dresden (DE)
  • Hans Langendijk, Groningen (NL)
  • David Sebag-Montefiori, Leeds (UK)
  • Petra Witt, Uppsala (SE)
  • Cai Grau, Aarhus (DK)

Panel discussion

16.40-18.40 Poster discussions and -bar

19:00-21:00 Welcome reception at Hotel Marselis, with optional guided tour of Memorial Park and Royal Gardens.


Thursday May 23, 2019

06:45 The BiGART early morning run - 5 km guided run in the forests around Marselisborg

08:10-10:00 Session 3: Normal tissue complications and therapeutic ratio in radiotherapy

Moderators: Hans Langendijk and Ludvig Muren

Invited speakers (20 min):

  • Joseph Deasy, New York (US): Determinants of outcomes following thoracic radiotherapy
  • Daniel Indelicato, Jacksonville (US): Do we need a different brainstem dose-effect model for protons?
  • Ivan Vogelius, Copenhagen (DK): Towards registry-based normal tissue complication modelling
  • Yolande Lievens, Ghent (BE): The value of radiotherapy: a multifaceted concept

Proffered papers (10 min):

  • Lene Haldbo-Classen, Aarhus (DK): Cognitive function after radiation therapy for brain tumours in adults
  • Christian Rønn Hansen, Odense (DK): NTCP model validation for selection of patients to a randomized controlled trial, DAHANCA35
  • Jesper Pedersen, Aarhus (DK): Normal tissue complication probability models for late rectal morbidity after proton therapy of 1036 prostate cancer patients


Coffee break


10:30-12:10 Session 4: Treatment planning, artificial intelligence and automation

Moderators: Sara Thörnqvist and Stine Korreman

Invited speakers (20 min):

  • Max Dahele, Amsterdam (NL): Integrating automated treatment planning and AI-based segmentation: ready for clinical use
  • Tufve Nyholm, Umeå (SE): Deep learning in radiotherapy - thoughts about training, applications and introduction
  • Mischa Hoogeman, Rotterdam (NL): Treatment plan automation for online adaption (in proton therapy)

Proffered papers (10 min):

  • Michael Matter, Villigen (CH): IMPT plan generation in under ten seconds
  • Christopher Kurz, Munich (DE): MR-only synthetic CT generation for MRI-guided proton therapy of the prostate using a conditional generative adversarial network
  • Søren Agergaard, Odense (DK): Automatically generated treatment plans for high risk prostate cancer
  • Franziska Knuth, Trondheim (NO): Functional MR-based automatic tumour segmentation of rectal cancer


12:10-12:30 ESTRO vision: Optimal Health for All in 2030 – what will be the role of Radiation Oncology?

Moderator: Cai Grau

  • Umberto Ricardi, Torino (IT) 

Lunch break

13:30-15:00 Session 5: Clinical radiotherapy - outcomes and new approaches: Breast, lung and GU

Moderators: Vincenzo Valentini and Birgitte Offersen

Invited speakers (20 min):

  • Philip Poortmans, Paris (FR): The quest for the right balance in breast cancer radiation therapy
  • Dirk De Ruysscher, Maastricht (NL): Advances in lung cancer radiation oncology

Proffered papers (10 min):

  • Marianne Knap, Aarhus (DK): Clinical outcome over a ten-year period of continuously development in radiotherapy for lung cancer patients treated at Aarhus University Hospital
  • Thomas V. Lacoppidan, Copenhagen (DK): Histology remains the strongest predictor of first failure site for locally advanced Non-Small Cell Lung Cancer in a competing risk model after inclusion of volumetric data
  • Patrick Berkovic, Leuven (BE): Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
  • Olfred Hansen, Odense (DK): Outcome after stereotactic radiotherapy in elderly patients with early non-small lung cancer
  • Ghazaleh Ghobadi, Amsterdam (NL): Spatial mapping of Gleason grade using multi-parametric MRI for dose differentiations in radiotherapy for prostate cancer

Coffee break

15:30-16:30 Session 6: Image-guidance and motion management

Moderators: Christopher Kurz and Kari Tanderup

Invited speakers (20 min):                                                                                                                                             

  • Faisal Mahmood, Odense (DK): MR-guided radiotherapy – more than just geometrical precision?
  • Aswin Hoffmann, Dresden (DE): Experimental results from a first hybrid MR-proton therapy research system

Proffered papers (10 min):

  • Per Poulsen, Aarhus (DK): Automatic detection of heart irradiation in cine MV images during breast cancer radiotherapy
  • Anni Lundgaard, Copenhagen (DK): The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study

16:30-18:30 Poster discussions and -bar

19:00-22:30 Dinner at Varna Palæet                                                                                              


Friday May 24, 2019


08:30-9:45 Session 7: Emerging concepts and techniques

Moderators: (tbc)

Invited speakers (20 min):

  • Katia Parodi, Munich (DE): Towards a novel small animal proton irradiation platform: the SIRMIO project
  • Marco Durante, Darmstadt (DE): Charged particles and immunotherapy: the perfect combination?

Proffered papers (10 min):

  • Anne Marit Rykkelid, Oslo (NO): Very high RBE values found at the distal end of the proton Bragg peak
  • Armin Lühr, Dresden (DE): Prediction of MR image changes in glioma patients for evaluation of proton RBE variability
  • Simon Skouboe, Aarhus (DK): First real-time motion-including tumor dose reconstruction during clinical radiotherapy treatments

Coffee break

10:15-11:45 Session 8: Clinical radiotherapy - outcomes and new approaches: Brain, head & neck and GI

Moderators: Ivan Vogelius and Jesper Grau Eriksen

Invited speakers (20 min):

  • ­­Pierre Blanchard, Paris (FR): Individual patient data meta-analyses in Head & Neck cancers – past, present & future.
  • Vincenzo Valentini, Rome (IT): Emerging trend in the treatment of upper GI cancers
  • Bruce Minsky, Houston (US): Emerging trends in the treatment of rectal cancer

Proffered papers (10 min):

  • Anouk Trip, Amsterdam (NL): Biological target volume based on DTI-MRI in postoperative chemoradiotherapy for glioblastoma
  • Jørgen Johansen, Odense (DK): Osteoradionecrosis after radiotherapy of patients with head and neck cancer: Incidence, risk factors, and mandibular dose-volume effects
  • Mette Saksø, Aarhus (DK): The DAHANCA 28 study: Accelerated hyperfractionated radiotherapy with concomitant cisplatin and nimorazole for locally advanced p16 negative HNSCC

11:45-12:00 Poster prizes and closing remarks

12:00 Farewell. Lunch box



Wednesday - poster discussion groups 1,3,5,7


Poster discussion group 1: Normal tissue morbidity and models

Moderators: Joseph Deasy and Christian Rønn Hansen

  • Julie Killerup Kaae, Odense (DK): Relation between patient and physician rated Xerostomia and dose to oral cavity and salivary glands for Head and Neck Cancer patients after radiotherapy
  • Katherina Farr, Aarhus (DK): Patient reported symptoms and quality of life analysis before and after definitive chemo-radiotherapy for non-small cell lung cancer: correlation with radiation pneumonitis
  • Christina Maria Lutz, Aarhus (DK): Pulmonary toxicities in a prospectively scored trial for non-small cell lung cancer
  • Tine Bisballe Nyeng, Aarhus (DK): Functional lung volumes obtained from SPECT-CT do not define the same voxels as functional lung volumes obtained from 4D-CT.
  • Jerzy Wydmański, Gliwice (PL): Radiation-induced injury of the exocrine pancreas during chemoradiotherapy for gastric cancer.
  • Oscar Casares-Magaz, Aarhus (DK): A case-control study of the associations between delivered rectal dose and gastro-intestinal toxicity following high-precision radiotherapy for prostate cancer
  • Morten Egeberg Evensen, Oslo (NO): Normal tissue complication probability modelling for plan evaluation in children with brain tumours referred to proton therapy
  • Anders Schwartz Vittrup, Aarhus (DK): Reporting of late morbidity after radiotherapy in large prospective studies: A descriptive review of the current practice.


Poster discussion group 3: Adaptation and response assessment

Moderators: Einar Dale and Lone Hoffmann

  • Faisal Mahmood, Odense (DK): Brain metastases size and internal diffusion during radiotherapy is non-intuitively related to treatment outcome
  • Maja Bendtsen Sharma, Aarhus (DK): Fluid variability in maxillary sinus during radiotherapy for sinonasal carcinoma
  • Zeno Gouw, Amsterdam (NL): Feasibility of serial FDG-PET guided adaptive radiotherapy for head and neck cancer
  • Ditte Sloth Møller, Aarhus (DK): Deep Inspiration Breath Hold for lung and lymphoma cancer patients: How stable is the Breath Hold during treatment?
  • Kathrin Surmann, Maastricht (NL): Anatomical changes and patient selection for dose-guided adaptive radiotherapy in lung cancer patients
  • Harald Spejlborg, Aarhus (DK): Delivered heart doses estimated from CINE acquisitions during tangential breast irradiation under deep inspiratory breath hold – is risk of excess heart dose initially predictable?
  • Gergely Antal, Kaposvar: Evaluation of prostate SABR verification workflow using triggered kV-imaging in combination with pre- and post-RT CBCT focusing on target coverage
  • Kia Busch, Aarhus (DK): On-line dose-guidance to account for inter-fractional motion during proton therapy


Poster discussion group 5: Imaging developments

Moderators: Tufve Nyholm and Morten Busk

  • Mikkel Holm Vendelbo, Aarhus (DK): PET imaging of tumor IGF-1 receptor expression and early treatment response during receptor targeting as a means to personalize treatment
  • Morten Busk, Aarhus (DK): Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant sub-volumes
  • Severin Langberg, Ås (NO): Establishing a complete radiomics framework for biomarker identification and outcome prediction using PET/CT images of head & neck cancers
  • Bertrand Pouymayou, Zürich (CH): Analysis of lymphatic metastasis and progression patterns for clinical target volume (CTV) definition in head and neck squamous cell carcinoma (HNSCC)
  • Marta Bogowicz, Zurich (CH): Perfusion CT radiomics depicts tumor biology and predicts tumor control in head and neck squamous cell carcinoma
  • Aurora Rosvoll Groendahl, Ås (NO): Automatic tumour delineation of head and neck cancers in PET/CT images using thresholding and machine learning methods
  • Tiril Hillestad, Oslo (NO): Imaging hypoxia levels in cervical cancer by DCE-MRI
  • Malgorzata Stapor-Fudzinska, Gliwice (PL): Use of the 68Ga-DOTATATE PET/CT/MRI imaging for stereotactic radiosurgery treatment planning for patients with meningiomas


Poster discussion group 7: Emerging delivery and verification strategies

Moderators: Eirik Malinen and Ole Nørrevang

  • Steven van de Water, Villigen (CH): Towards FLASH proton therapy: Exploring dose rate distributions for different treatment planning paradigms and PBS machine characteristics
  • Anne Holm, Aarhus (DK): Proof of concept: Shaping the lateral beam penumbra of a proton beam by non-linear beam optics
  • Sebastian Neppl, Munich (DE): Dosimetric evaluation of 2D and 3D Unet-generated pseudoCTs for proton therapy of brain lesions
  • Anders Bertelsen, Odense (DK): First clinical experience with a high field 1.5 T MR linac
  • Mikkel Skaarup, Copenhagen (DK): A dual energy material decomposition algorithm for clinical cone-beam computed tomography
  • Andreas Gravgaard Andersen, Aarhus (DK): Scatter-corrected CBCTs for online water-equivalent path length calculations in proton therapy
  • Julia Bauer, Heidelberg (DE): Improving the modelling of irradiation-induced brain activation for in-vivo PET verification of proton therapy
  • Britta Weber, Aarhus (DK): Hyperpolarized MR as a new potential method for early response monitoring in pancreatic cancer


Thursday - poster discussion groups 2,4,6,8


Poster discussion group 2: Clinical trials and outcomes

Moderators: Pierre Blanchard and Marianne Nordsmark

  • Dirk de Ruysscher, Maastricht (NL): Health-related quality of life (HRQoL) after Prophylactic Cranial Irradiation (PCI) for Stage III NSCLC Patients in the NVALT-11 Randomized Phase III Trial
  • Daniel Indelicato, Jacksonville (US): Outcomes following proton therapy for group III pelvic rhabdomyosarcoma
  • Jens Overgaard, Aarhus (DK): DAHANCA 9 - The best Dahanca study that never was. A incomplete randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with HNSCC.
  • Sławomir Blamek, Gliwice (PL): Analysis of dose-volume relationship and clinical factors in relation to local control in patients with brain metastases treated with stereotactic radiosurgery or hypofractionated stereotactic radiotherapy
  • Eric Meline, Odense (DK): The effect of tumor laterality on survival for non-small cell lung cancer patients treated with definitive radiotherapy
  • Azadeh Abravan, Manchester (UK): Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
  • Morten Nielsen, Odense (DK): Initial experiences with hippocampus-sparing whole-brain radiotherapy for lung cancer patients
  • Eva Holtved, Odense (DK): A single institution experience with IMRT-planned definite chemo-radiotherapy to an unselected population of patients with inoperable, unresectable or recurrent esophageal cancer


Poster discussion group 4: Intra-fractional challenges

Moderators: Aswin Hoffmann (tbc) and Per Poulsen

  • Miriam Krieger, Villigen (CH): Probabilistic ITV definition to account for respiratory motion variability in PBS proton treatments
  • Frank Emert, Villigen (CH): Assessment of two different techniques for respiratory motion mitigation for lung cancer treatment with proton therapy using MRI – a clinical study
  • Toke Printz Ringbæk, Marburg (DE): Calculation of the beam-modulation effect of the lung in raster scanning particle therapy with deterministic pencil beam algorithms
  • Ye Zhang, Villigen (CH): Motion model based PBS proton beam tracking for lung tumour treatments using real time liver ultrasound as online image guidance: proof-of-concept
  • Casper Gammelmark Muurholm, Aarhus (DK): Real-time dose-guided radiation therapy
  • Thomas Ravkilde, Aarhus (DK): Experimental validation of an MLC tracking treatment simulator with dose reconstruction
  • Mirjana Josipovic, Copenhagen (DK): Deep inspiration breath hold in locally advanced lung cancer radiotherapy: validation of intra-fractional geometric uncertainties in the INHALE trial


Poster discussion group 6: Proton RBE studies

Moderators: Tracy Underwood and Brita Sørensen

  • Johannes Müller, Dresden (DE): Development of a novel setup for high precision image-guided proton irradiation of brain sub-volumes in small animals
  • Jan Hofmaier, Munich (DE): Variance-based sensitivity analysis for uncertainties in proton therapy: Effect of simultaneous uncertainties in range, positioning and RBE model predictions on RBE-weighted dose distributions
  • Helge Henjum, Bergen (NO): Implementation and exploration of biological optimization in proton therapy
  • Jakob Ödén, Stockholm (SE): Spatial correlation of linear energy transfer and relative biological effectiveness with treatment related toxicities following proton therapy for intracranial tumours
  • Laura Toussaint, Aarhus (DK): Biological doses with constant and variable relative biological effectiveness in proton arc therapy for pediatric brain radiotherapy
  • Stine Korreman, Aarhus (DK): Proton therapy for esophageal cancer; variable relative biological effect and heart dose
  • Ole Otterlei, Bergen (NO): Variation in biological doses in cognitive structures using different models for the relative biological effectiveness of proton therapy for pediatric brain tumors
  • Apostolos Raptis, Stockholm (SE): The risk of second cancer from proton therapy for breast cancer: the impact of physiological motion and variable relative biological effectiveness (RBE)


Poster discussion group 8: Proton treatment planning and verification

Moderators: Mischa Hoogeman and Ditte Møller

  • Pernille Bræmer-Jensen, Aarhus (DK): Experimental validation of clinical proton stopping power calibration curves based on single energy CT and dual energy CT based monoenergetic images
  • Jesper Folsted Kallehauge, Aarhus (DK): Dose perturbation effect of titanium cranial implants in proton beam therapy.
  • Vicki Taasti, New York (US): Automated proton treatment planning and beam angle selection using Bayesian and hierarchical constrained optimization techniques
  • Lena Nenoff, Villigen (CH): Daily adaptive proton therapy: the key to use more effective field arrangements
  • Camilla Skinnerup Byskov, Aarhus (DK): Treatment plan comparison of proton vs photon therapy for low-grade gliomas
  • Raul Argota Perez, Aarhus (DK): Evaluation of a standard robust optimization method to anatomical variations for proton therapy in H&N patients.
  • Malene Ehrenreich, Copenhagen (DK): A proton treatment planning strategy for breast cancer patients with IMN involvement
  • Maria Fuglsang Jensen, Aarhus (DK): A simulator of proton pencil beam scanning delivery
  • Sytze Brandenburg, Groningen (NL): Novel infrastructure for image guided preclinical research in particle therapy


POSTERS ON GENERAL DISPLAY, to be viewed during coffee breaks and lunch

  • Adam Idasiak, Gliwice (PL): Tumor Regression Grading After Preoperative Hyperfractionated Radiotherapy / Chemoradiotherapy for Locally Advanced Rectal Cancers: Interim Analysis of a  Phase III Clinical Study
  • Lone Hoffmann, Aarhus (DK): Optimal beam-angle selection and knowledge-based planning significantly reduces dose to organs at risk for lung cancer patients
  • Sofia Spampinato, Aarhus (DK): Functional sub-structures of the lower urinary tract in gynaecological radiotherapy
  • Diem Vuong, Zurich (CH): Comparison of robust to standardized CT radiomics models to predict OS for NSCLC patients
  • Lars Hjorth Praestegaard, Aarhus (DK): Replacement of EPID-based treatment QA by treatment analysis software
  • Nina Niebuhr, Heidelberg (DE): Biologically consistent dose accumulation and its uncertainties and implications in pelvic patients
  • Moritz Rabe, Munich (DE): Real-time 4D-MRI-based geometrical analysis of interfractional changes of internal target volumes of moving lung tumors
  • Susan Blak Nyrup Biancardo, Herlev (DK): Evaluation of image guidance workflows for precise and efficient delivery of non-coplanar stereotactic radiosurgery of brain metastases using Varians HyperArc technique with and without BrainLabs ExacTrac.
  • Susanne Nørring Bekke, Herlev (DK): Improvement in surface-based setup for breast cancer radiotherapy with surface guided correction of arm posture
  • Jolanta Hansen, Aarhus (DK): Heart and lung dose for free breathing and deep inspiration breath-hold based radiotherapy in the treatment of lymphomas/sarcomas and lung cancer patients.
  • Ruta Zukauskaite, Odense (DK): Accuracy of the deformable image registration software MIM for recurrence mapping in the head and neck region
  • Boguslaw Maciejewski, Gliwice (PL): Impact of Total Nodal Volume (VtN) on local control of primary tumour (VGTV) in radiotherapy (IMRT) for oropharyngeal cancer
  • Gitte Persson, Herlev (DK): Are pancoast tumours robust candidates for proton spot scanning?
  • Line Bjerregaard Stick, Copenhagen (DK): Stereotactic radiotherapy for liver metastases in free breathing vs. breath hold – preliminary results
  • Wiviann Ottosson, Herlev (DK): The dosimetric effect of changing the dose calculation algorithm on heterogeneous FDG-guided dose-escalated treatment plans for locally advanced NSCLC patients enrolled in the NARLAL2 phase III trial
  • Yasmin Lassen, Aarhus (DK): Proton and Photon Salvage Craniospinal Radiotherapy, a comparison of the intracranial part of the two treatment modalities
  • Laura Patricia Kaplan, Aarhus (DK): Evaluation of quantitative metrics to describe a physical dose distribution
  • Kathrin Bartelheimer, Heidelberg (DE): Anthropomorphic chainmail for fast soft-tissue deformation in human anatomies
  • Kenneth Jensen, Aarhus (DK): Re-irradiation using intensity modulated proton therapy (IMPT) for recurrent or new primary head and neck cancer (DAHANCA 37)
  • Ljubica Kravic, Bergen (NO): Tumor classification with PET/MR in cervical cancer using a multivariate logit model calibrated to published imaging associations on pathology and response
  • Kirsten Legård Jakobsen, Næstved (DK): A comparison between IMRT, VMAT and conventional planning of complex mammacases with irradiation of the internal mammary nodes
  • Kinga Jeleń, Krakow (PL): A model for RBE distribution in proton radiotherapy based on α / β ratio and linear energy transfer
  • Marcin Miszczyk, Gliwice (PL): Are Tumour Volume (VGTV) and Total Tumour Volume (VT) superior to the TNM staging as efficacy predictors in radiotherapy for oropharyngeal cancer?
  • Bernt Nordin, Stockholm (SE): Dose escalation in moving targets. Clinical experiences from the first five years of adaptive MR-guided radiotherapy.


Poster discussion at BiGART2017